Next Article in Journal / Special Issue
What Has 30 Years of HIV Vaccine Research Taught Us?
Previous Article in Journal / Special Issue
Developing Combined HIV Vaccine Strategies for a Functional Cure
Vaccines 2013, 1(4), 497-512; doi:10.3390/vaccines1040497
Review

Envelope Glycoprotein Trimers as HIV-1 Vaccine Immunogens

The Sir William Dunn School of Pathology, The University of Oxford, South Parks Road, Oxford OX13RE, UK
Received: 6 September 2013 / Revised: 11 October 2013 / Accepted: 12 October 2013 / Published: 28 October 2013
(This article belongs to the Special Issue HIV Vaccines)
View Full-Text   |   Download PDF [580 KB, uploaded 28 October 2013]   |   Browse Figures

Abstract

The HIV-1 envelope glycoprotein spike is the target of neutralizing antibody attack, and hence represents the only relevant viral antigen for antibody-based vaccine design. Various approaches have been attempted to recapitulate Env in membrane-anchored and soluble forms, and these will be discussed here in the context of recent successes and challenges still to be overcome.
Keywords: HIV-1; vaccine; neutralizing antibodies; envelope glycoproteins; trimer HIV-1; vaccine; neutralizing antibodies; envelope glycoproteins; trimer
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Export to BibTeX |
EndNote


MDPI and ACS Style

Sattentau, Q.J. Envelope Glycoprotein Trimers as HIV-1 Vaccine Immunogens. Vaccines 2013, 1, 497-512.

View more citation formats

Article Metrics

Comments

Citing Articles

[Return to top]
Vaccines EISSN 2076-393X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert